Scandinavian Real Heart (HEART) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
26 Oct, 2026Financial performance review
FY2025 income statement and balance sheet adopted; retained earnings carried forward.
Board and executive committee updates
Board set at six members, with no deputies; Azad Najar, Oliver Voigt, Giovanni Lauricella, Stuart McConchie, Oskar Mellgren and Mia Tomczak re-elected through the next AGM.
Oskar Mellgren elected Chairman; Board and CEO who served during FY2025 discharged from liability.
Chairman’s fee set at SEK 160,000 and each other non-employed Board member’s fee at SEK 77,500.
Dividend announcements
No dividend for FY2025; retained earnings carried forward.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Scandinavian Real Heart
- Advanced toward clinical readiness with new patents, funding, and improved financial stability.HEART
H1 2026 - Preclinical progress, patent expansion, and strong financing position clinical readiness for 2026.HEARTQ4 2025
- Jan. 13–27 rights issue funds Realheart TAH development and regulatory steps.HEARTStatus update
- Patent wins, capital raises, and scientific validation drive progress despite ongoing losses.HEARTQ2 2025
- Preclinical progress, new funding, and strategic alliances drive Realheart toward clinical trials.HEARTQ3 2024
- SEK 24.3 million raised to fund Realheart's artificial heart preclinical program, cash runway to Q4 2025.HEARTQ2 2024
- SEK 30.2 million raised as Realheart advances artificial heart to clinical trial readiness.HEARTQ1 2025
- Key preclinical progress and FDA HUD status position Realheart for clinical trial initiation.HEARTQ4 2024